Cargando…

Roles of neutrophil/lymphocyte ratio in prognosis and in differentiation of potential beneficiaries in HER2-positive breast cancer with trastuzumab therapy

BACKGROUND: The relationship of neutrophil/lymphocyte ratio (NLR) to prognosis of HER2-positive breast cancer (BC) is not well studied. We aimed to assess the prognostic role of NLR in HER2-positive BC patients treated with or without trastuzumab. METHODS: The clinical data of 843 HER2-positive BC p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ding, Nianhua, Huang, Juan, Li, Ningsha, Yuan, Jiaqi, Wang, Shouman, Xiao, Zhi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7082930/ https://www.ncbi.nlm.nih.gov/pubmed/32192443 http://dx.doi.org/10.1186/s12885-020-06750-3

Ejemplares similares

Significance of baseline neutrophil-to-lymphocyte ratio for progression-free survival of patients with HER2-positive breast cancer treated with trastuzumab emtansine
por: Imamura, Michiko, et al.
Publicado: (2019)

Prognostic Value of Pretreatment Neutrophil-to-Lymphocyte Ratio in HER2-Positive Metastatic Breast Cancer
por: Shao, Bin, et al.
Publicado: (2022)

Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer
por: Yang, Jiangping, et al.
Publicado: (2022)

Neutrophil-to-Lymphocyte Ratio in Prognosis of Gastric Cancer
por: Balta, Sevket, et al.
Publicado: (2013)

A high absolute lymphocyte count predicts a poor prognosis in HER-2- positive breast cancer patients treated with trastuzumab
por: Hong, Jin, et al.
Publicado: (2019)

Dynamic changes of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio predicts breast cancer prognosis
por: Kim, Ju-Yeon, et al.
Publicado: (2020)

The prognostic and predictive role of the neutrophil-to-lymphocyte ratio and the monocyte-to-lymphocyte ratio in early breast cancer, especially in the HER2+ subtype
por: Tiainen, Satu, et al.
Publicado: (2020)

Preoperative Neutrophil to Lymphocyte Ratio and Platelet to Lymphocyte Ratio are Associated with the Prognosis of Group 3 and Group 4 Medulloblastoma
por: Li, Ke, et al.
Publicado: (2019)

HER2/CEP17 Ratios and Clinical Outcome in HER2-Positive Early Breast Cancer Undergoing Trastuzumab-Containing Therapy
por: Stocker, Albina, et al.
Publicado: (2016)

Impact on the survival of neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, and monocyte-lymphocyte ratio on prognosis in children with Hodgkin lymphoma
por: Ertan, Kubra, et al.
Publicado: (2022)

Molecular portraits and trastuzumab responsiveness of estrogen receptor-positive, progesterone receptor-positive, and HER2-positive breast cancer
por: Zhao, Shen, et al.
Publicado: (2019)

PTEN loss and level of HER2 amplification is associated with trastuzumab resistance and prognosis in HER2-positive gastric cancer
por: Kim, Chan, et al.
Publicado: (2017)

Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio as Potential Predictors of Prognosis in Acute Ischemic Stroke
por: Chen, Cuiping, et al.
Publicado: (2021)

Prognostic and predictive role of spatially positioned tumour infiltrating lymphocytes in metastatic HER2 positive breast cancer treated with trastuzumab
por: Honkanen, Tiia J., et al.
Publicado: (2017)

Elevated neutrophil-to-lymphocyte ratio and monocyte-to-lymphocyte ratio and decreased platelet-to-lymphocyte ratio are associated with poor prognosis in multiple myeloma
por: Shi, Lihui, et al.
Publicado: (2016)

The Hippo Transducer YAP/TAZ as a Biomarker of Therapeutic Response and Prognosis in Trastuzumab-Based Neoadjuvant Therapy Treated HER2-Positive Breast Cancer Patients
por: Yuan, Jia-qi, et al.
Publicado: (2020)

HER2-positive breast cancer patients receiving trastuzumab treatment obtain prognosis comparable with that of HER2-negative breast cancer patients
por: Qin, Tao, et al.
Publicado: (2013)

Neutrophil to lymphocyte ratio predicts prognosis in unresectable pancreatic cancer
por: Iwai, Naoto, et al.
Publicado: (2020)

The importance of the neutrophil‐to‐lymphocyte ratio in the prognosis of glioma and its subtypes
por: Linhares, Paulo, et al.
Publicado: (2019)

The Neutrophil-Lymphocyte Ratio Is Positively Correlated with Aggression in Schizophrenia
por: Tong, Zhu, et al.
Publicado: (2022)

Prognostic Value of Neutrophil–Lymphocyte Ratio, Platelet–Lymphocyte Ratio, and Combined Neutrophil–Lymphocyte Ratio and Platelet–Lymphocyte Ratio in Stage IV Advanced Gastric Cancer
por: Wang, Huan, et al.
Publicado: (2020)

Potential Biomarkers Associated with Prognosis and Trastuzumab Response in HER2+ Breast Cancer
por: Castro-Guijarro, Ana Carla, et al.
Publicado: (2023)

Expression of breast cancer stem cell markers as predictors of prognosis and response to trastuzumab in HER2-positive breast cancer
por: Seo, An Na, et al.
Publicado: (2016)

Role of trastuzumab emtansine in the treatment of HER2-positive breast cancer
por: Oostra, Drew R, et al.
Publicado: (2014)

Ado-Trastuzumab Emtansine in Metastatic HER2-Positive Breast Cancer
por: Callahan, Rena
Publicado: (2014)

Trastuzumab beyond progression in HER2‐positive metastatic breast cancer
por: Al‐Naqqash, Manwar, et al.
Publicado: (2021)

Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models
por: Veeraraghavan, Jamunarani, et al.
Publicado: (2021)

Termination of trastuzumab in HER2-positive metastatic breast cancer patients who received trastuzumab beyond progression
por: Dogan, Izzet, et al.
Publicado: (2023)

The Position of Neutrophils-To-Lymphocytes and Lymphocytes-To-Platelets Ratio as Predictive Markers of Progression and Prognosis in Patients with Non-Small Cell Lung Cancer
por: Minkov, Plamen, et al.
Publicado: (2018)

Prognostic Significance of Neutrophil-to-Lymphocyte Ratio and C-Reactive Protein/Albumin Ratio in Luminal Breast Cancers With HER2-Negativity
por: Chen, Fei, et al.
Publicado: (2022)

Usefulness of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in hormone-receptor-negative breast cancer
por: Liu, Chao, et al.
Publicado: (2016)

Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer
por: Soo Park, Ji, et al.
Publicado: (2017)

The neutrophil-to-lymphocyte ratio (NLR) predicts adrenocortical carcinoma and is correlated with the prognosis
por: Mochizuki, Taku, et al.
Publicado: (2017)

Higher neutrophil-lymphocyte ratio is associated with better prognosis of hepatocellular carcinoma
por: Li, Sheng-chao, et al.
Publicado: (2020)

The predictive role of the neutrophil–lymphocyte ratio in the prognosis of adult patients with stroke
por: Wan, Jinzhao, et al.
Publicado: (2020)

Neutrophil-to-lymphocyte ratio predicts the prognosis of stage II nasopharyngeal carcinoma
por: Pan, Xin-Bin, et al.
Publicado: (2019)

Prognostic utility of tumor-infiltrating lymphocytes in residual tumor after neoadjuvant chemotherapy with trastuzumab for HER2-positive breast cancer
por: Kurozumi, Sasagu, et al.
Publicado: (2019)

Therapeutic Effect of Trastuzumab in Neoadjuvant-Treated HER2-Positive Breast Cancer with Low Infiltrating Level of Tumor-Infiltrating Lymphocytes
por: Liu, Shiwei, et al.
Publicado: (2020)

Neutrophil: lymphocyte ratio is positively associated with subclinical diabetic cardiomyopathy
por: Huang, Xiaoli, et al.
Publicado: (2020)

Neutrophil to lymphocyte ratio is a prognosis factor for post-operative pneumonia in aneurysmal subarachnoid hemorrhage patients
por: Chen, Yue, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_i59keu01q53r0noqec2b62f2sb